Literature DB >> 19710668

Should cancer screening be routine in rheumatoid arthritis?

Eric L Matteson.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19710668     DOI： 10.1038/nrrheum.2009.173

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study.

Authors:  J Askling; L Klareskog; P Blomqvist; M Fored; N Feltelius
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

2.  Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.

Authors:  E Baecklund; A Ekbom; P Sparén; N Feltelius; L Klareskog
Journal:  BMJ       Date:  1998-07-18

3.  Lymphoma risk in psoriasis: results of the PUVA follow-up study.

Authors:  Robert S Stern
Journal:  Arch Dermatol       Date:  2006-09

4.  Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.

Authors:  Johan Askling; C Michael Fored; Lena Brandt; Eva Baecklund; Lennart Bertilsson; Nils Feltelius; Lars Cöster; Pierre Geborek; Lennart T Jacobsson; Staffan Lindblad; Jörgen Lysholm; Solbritt Rantapää-Dahlqvist; Tore Saxne; Ronald F van Vollenhoven; Lars Klareskog
Journal:  Ann Rheum Dis       Date:  2007-01-29       Impact factor: 19.103

Review 5.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

Review 6.  Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures?

Authors:  Carlotta Nannini; Fabrizio Cantini; Laura Niccoli; Emanuele Cassarà; Carlo Salvarani; Ignazio Olivieri; Edward V Lally
Journal:  Arthritis Rheum       Date:  2009-06-15

7.  Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2004-06

8.  Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study.

Authors:  Karin Hellgren; Anastasia Iliadou; Richard Rosenquist; Nils Feltelius; Carin Backlin; Gunilla Enblad; Johan Askling; Eva Baecklund
Journal:  Ann Rheum Dis       Date:  2009-05-12       Impact factor: 19.103

9.  Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.

Authors:  J Askling; E Baecklund; F Granath; P Geborek; M Fored; C Backlin; L Bertilsson; L Cöster; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; R van Vollenhoven; L Klareskog; N Feltelius
Journal:  Ann Rheum Dis       Date:  2008-05-08       Impact factor: 19.103

Review 10.  Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials.

Authors:  T Bongartz; F C Warren; D Mines; E L Matteson; K R Abrams; A J Sutton
Journal:  Ann Rheum Dis       Date:  2008-11-19       Impact factor: 19.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.